Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–73.

PubMed  PubMed Central  Google Scholar 

Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149–65.

PubMed  PubMed Central  Google Scholar 

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.

PubMed  PubMed Central  Google Scholar 

Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.

PubMed  PubMed Central  Google Scholar 

Kang W, Feng Z, Luo J, He Z, Liu J, Wu J, Rong P. Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies. Front Immunol. 2021;12: 689270.

PubMed  PubMed Central  Google Scholar 

Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023;19(8):525–37.

PubMed  Google Scholar 

Yang C, Cai YX, Wang ZF, Tian SF, Li ZQ. Tertiary lymphoid structures in the central nervous system. Trends Mol Med. 2024;31(6):509–21.

PubMed  Google Scholar 

Pimenta EM, Barnes BJ. Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. Cancers (Basel). 2014;6(2):969–97.

PubMed  Google Scholar 

Lv J, Zhang X, Zhou M, Yan J, Chao G, Zhang S. Tertiary lymphoid structures in colorectal cancer. Ann Med. 2024;56(1):2400314.

PubMed  PubMed Central  Google Scholar 

Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14(9):587.

PubMed  PubMed Central  Google Scholar 

Frisbie L, Buckanovich RJ, Coffman L. Carcinoma-associated mesenchymal stem/stromal cells: architects of the pro-tumorigenic tumor microenvironment. Stem Cells. 2022;40(8):705–15.

PubMed  PubMed Central  Google Scholar 

Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–86.

PubMed  PubMed Central  Google Scholar 

Shah K, Mallik SB, Gupta P, Iyer A. Targeting Tumour-Associated Fibroblasts in Cancers. Front Oncol. 2022;12: 908156.

PubMed  PubMed Central  Google Scholar 

Atiya H, Frisbie L, Pressimone C, Coffman L. Mesenchymal Stem Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1234:31–42.

PubMed  Google Scholar 

Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1): e12712.

PubMed  Google Scholar 

Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452–64.

PubMed  PubMed Central  Google Scholar 

Jiang Z, Zhou J, Li L, Liao S, He J, Zhou S, Zhou Y. Pericytes in the tumor microenvironment. Cancer Lett. 2023;556: 216074.

PubMed  Google Scholar 

Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.

PubMed  PubMed Central  Google Scholar 

Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Front Immunol. 2015;6:67.

PubMed  PubMed Central  Google Scholar 

Zhao R, Gao D. Innate Immunity and Tertiary Lymphoid Structures. Immunol Rev. 2025;332(1): e70052.

PubMed  Google Scholar 

Rossi A, Belmonte B, Carnevale S, Liotti A, De Rosa V, Jaillon S, et al. Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. Front Cell Dev Biol. 2022;10: 933113.

PubMed  PubMed Central  Google Scholar 

Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren’s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180(7):5130–40.

PubMed  Google Scholar 

Gaudino SJ, Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol. 2019;10:360.

PubMed  PubMed Central  Google Scholar 

Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A, et al. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application. Mol Cancer. 2024;23(1): 75.

PubMed  PubMed Central  Google Scholar 

Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9(1):225.

PubMed  PubMed Central  Google Scholar 

Germain C, Devi-Marulkar P, Knockaert S, Biton J, Kaplon H, Letaief L, et al. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. Front Immunol. 2021;12: 626776.

PubMed  PubMed Central  Google Scholar 

Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52–62.

PubMed  Google Scholar 

Petroni G, Pillozzi S, Antonuzzo L. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy. Cancer Res. 2024;84(8):1199–209.

PubMed  PubMed Central  Google Scholar 

Peyraud F, Guegan JP, Vanhersecke L, Brunet M, Teyssonneau D, Palmieri LJ, et al. Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. Med. 2025;6(1): 100546.

PubMed  Google Scholar 

Desai I, Thakur S, Pagariya P. Current advances in immunotherapy for cancer. Oral Oncol Rep. 2024;12: 100652.

Google Scholar 

Bai R, Cui J. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. Front Immunol. 2022;13: 890166.

PubMed  PubMed Central  Google Scholar 

Liu Y, Guo J, Huang L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics. 2020;10(7):3099–117.

PubMed  PubMed Central  Google Scholar 

Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13: 954992.

PubMed  PubMed Central  Google Scholar 

Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS ONE. 2012;7(8): e42274.

PubMed  PubMed Central  Google Scholar 

Tumino N, Fiore PF, Pelosi A, Moretta L, Vacca P. Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells. Semin Immunol. 2022;61–64: 101668.

PubMed  Google Scholar 

Liu Z, Meng X, Tang X, Zou W, He Y. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. Cancer Immunol Immunother. 2023;72(6):1505–21.

PubMed  Google Scholar 

Ucaryilmaz Metin C, Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. BMC Cancer. 2022;22(1):692.

PubMed  PubMed Central  Google Scholar 

Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211(8):1503–23.

PubMed  PubMed Central  Google Scholar 

Santolla MF, Vivacqua A, Lappano R, Rigiracciolo DC, Cirillo F, Galli GR, et al. GPER mediates a feedforward FGF2/FGFR1 paracrine activation coupling CAFs to cancer cells toward breast tumor progression. Cells. 2019;8(3):223.

PubMed  PubMed Central  Google Scholar 

Tao J, Gu Y, Zhang Z, Weng G, Liu Y, Ren J, et al. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. J Exp Clin Cancer Res. 2024;43(1):277.

PubMed  PubMed Central  Google Scholar 

Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, et al. GM-CSF mediates mesenchymal-epithelial cross-talk in pancreatic cancer. Cancer Discov. 2016;6(8):886–99.